1. We describe the use of four monoclonal antibodies (MAbs) to the rabbit liver growth hormone (GH) receptor and one raised against purified rat liver GH receptor to characterize liver receptor subtypes which differ in their hormone-binding regions. 2. The anti-(rat liver GH receptor) MAb both inhibited and precipitated rat and rabbit GH receptors, but only one-half of 125I-oGH (ovine GH) binding to liver microsomes could be inhibited by excess antibody. Conversely, only one-half of 125I-anti-(rat GH receptor) MAb binding was inhibited by excess oGH and Scatchard plots for this MAb exhibited two components.
INTRODUCTION
It is now well established that GH in several species exists not as a single peptide but as a family of peptides which differ in their bioassay and immunological properties (Russell et al., 1978; Moore et al., 1982; Baumann & Abramson, 1983; Chawla et al., 1983; Paladini et al., 1983; Hart et al., 1984) . Some of this variation arises at the transcriptional level, and some results from selective proteolysis of the mature, or 22 kDa, form of the hormone (Chawla et al., 1983; Paladini et al., 1983) . The functional importance of these variants is not clear, but in the human the 20 kDa and 22 kDa forms are found both in the pituitary and in the circulation (Baumann & Abramson, 1983) , and these differ in their effects on carbohydrate metabolism (Frigeri et al., 1979) .
Individual members of this peptide family could produce different effects on target organs either by interacting differently with a single class of receptor or by binding preferentially to particular types of receptor which mediate specific actions of GH. The existence of receptor subtypes could also explain the differences in dose-response curves, time courses, sensitivity to refractoriness and other phenomena described by Grichting et al. (1983) in their comparison of the different actions of GH in vitro. Evidence has recently been presented for the existence of tissue-specific prolactin receptors which may mediate the various actions of prolactin , and in that study evidence for 'iso-receptors' of other peptide hormones was summarized. This report describes the use of a panel of monoclonal antibodies to the GH receptor [recently developed in our laboratory (Barnard et al., 1984) ] to reveal receptor heterogeneity in the rabbit and rat liver.
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Abbreviations used: GH, growth hormone (somatotropin); PRL, prolactin; the prefixes h, o and r refer to the human, sheep and rat hormones respectively; MAb, monoclonal antibody; PEG, poly(ethylene glycol).
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MATERIALS AND METHODS Materials GH (oGH S-12 and 1-3), GH (hGH HS 2019G), rGH (1-4), and PRL (oPRL S-15) were gifts from the National Pituitary Agency (Baltimore, MD, U.S.A.). GH for receptor preparation was kindly provided by the Human Pituitary Advisory Committee of Australia.
All hormones except rGH were iodinated by the lactoperoxidase method of Thorell & Johansson (1971) as described previously (Waters & Friesen, 1979) . Rat GH was iodinated by the lodogen method of Salacinski et al. (1981) . Hormones were fractionated on a Sephadex G-100 column (1.7 cm x 50 cm) after iodination. MAbs were iodinated by the lactoperoxidase or lodogen methods and were similarly fractionated. Specific radioactivities of iodinated MAbs were in the range 50-150 ,tCi/,/g. Rabbit anti-(mouse immunoglobins) were purchased from DAKO Immunoglobulins (Copenhagen, Denmark). Anti-isotype antibodies were obtained from Miles Laboratories (Elkhart, IN, U.S.A.) .
Reagents for enzyme assays were obtained from Sigma or BDH.
Reagents for hybridoma production RPMI-1640 medium was purchased from Flow Laboratories, HB1I1 medium was obtained from Hana Biologicals (Berkeley, NJ, U.S.A.), all other reagents were obtained from Sigma. Costar 24-well plates were purchased from Costar (Cambridge, MA, U.S.A.) and flexible 96-microwell poly(vinyl chloride) microtiter plates were obtained from Dynatech Laboratories (Alexandria, VA, U.S.A.).
Preparation of receptor-containing fractions
The GH receptor preparations used in this study are derived from three stages in the purification method for rabbit GH receptor, as described previously (Waters & Friesen, 1979) . The majority of the studies involving inhibition of 1251-hormone binding were done with crude microsomal (100000 g, 60 min) fractions of late pregnant rabbit liver or rat liver. Immunoprecipitation studies were undertaken with either Triton X-100-solubilized (10 v/v) extracts ofthe microsomal membranes (300000 g, 90 min supernatants), or with rabbit liver GH receptor partially purified from such supernatants by differential affinity chromatography on an hGH affinity column (Waters & Friesen, 1979) . Inhibition studies were also performed with this partially purified GH receptor. Affinity-purified rat GH receptor was used in the hybridoma screening procedure described below. Rabbit liver cytosol (100000 g, 60 min, supernatant filtered through Whatman no. 541 paper to remove fat) was also used for some precipitation and inhibition studies.
Receptor-binding assays were carried out according to the method of Barnard et al. (1984) using 125I-oGH, 125I-hGH or 125I-rGH. Inhibition and precipitation assays with rabbit liver cytosol were carried out by standard methods (Waters & Friesen, 1979) (Waters & Friesen, 1979) ] was incorporated into the preincubation step of the inhibition assay. This enables PEG precipitation of receptorhormone complexes which are otherwise PEG-soluble (Barnard et al., 1984) . All data has been plotted as a percentage of specific binding, i.e. non-specific binding has been subtracted. Specific, ligand-displaceable binding is determined in binding control tubes with parallel, serial dilutions of an anti-Brucella MAb of the same isotype (IgG,K) as the test MAb.
The fluorescence method of Stowell et al. (1978) was used to determine the protein concentration of affinitypurified GH receptor preparations. Immunodepletion studies Affinity-purified GH receptor or rabbit liver cytosol (400,1; at four times the concentration required for maximum specific binding of 1251I-GH in the radioreceptor assay) was incubated with 400 ,1 of test MAb (at 1: 1000 dilution in RRA buffer) for 3 h at 4 'C. Rabbit anti-(mouse globulins) (0.4 ml at the appropriate dilution) and normal mouse serum (at 1:100 dilution in RRA buffer, 0.4 ml) were then added aiid incubation was continued for 90 min at room temperature. The reaction mixture was centrifuged at 1600 g for 25 min at 4 'C and the supernatant was tested (in parallel with undepleted GH receptor) for residual GH binding activity in a standard radioreceptor assay with added MAb 1 to detect residual PEG-soluble GH receptor.
Inhibition of 1251-MAb binding to GH receptor by GH
This was assayed in the same manner as the standard inhibition assay (Waters & Friesen, 1979) , but using radiolabelled antibody and an appropriate dilution of membranes (Barnard et al., 1984) .
Determination of affinity constants (KJ)
Binding affinities ofMAbs were estimated by Scatchard analysis (Scatchard, 1949) of 1251-MAb binding to pretitrated rabbit liver or rat liver membranes in the presence of increasing concentrations of corresponding unlabelled MAb (Barnard et al., 1984) . Curves were fitted with the Rodbard-Munson program SCAFIT provided by the Biomedical Computing Technology Information Center (Vanderbilt, TN, U.S.A.). Immunization and hybridoma production Production of rabbit-specific MAbs. The immunization protocol, screening procedure and characterization of MAbs 1, 2, 5 and 7 has been described in detail previously (Barnard et al., 1984) .
Production of MAb 263 which recognizes a cross-species determinant. hGH affinity-purified rat GH receptor was prepared by the method of Waters & Friesen, (1979) . The purified receptor had a specific activity of 900 fmol/mg. BALB/c mice (previously immunized with purified rabbit GH receptor) were given a series of subcutaneous injections of 0.2 ml of rat GH receptor (0.8 mg) in Freunds' complete adjuvant at 2 week intervals. This was followed by an intraperitoneal boost of 0.4 mg in normal saline. At 4 days after the boost injection, serum from these mice inhibited 5000 of 125I-oGH binding to rat membranes at a final dilution of 1:400.
At 3 days after the boost injection, splenic lymphocytes from three mice were pooled and fused with NS-1 myeloma cells, as described by Barnard et al. (1984 Isolation of blood sinusoidal rabbit plasma membranes For subfractionation studies, plasma membranes were prepared using a modification, by Wisher & Evans (1975) , of the method of Touster et al. (1970) . Unperfused liver (30 g) from a fasted rabbit was dispersed in 0.25 Msucrose/5 mM-Tris/HCl, pH 8.0, using two strokes of a loose-fitting Dounce homogenizer. Further homogenization was performed with two up-and-down strokes in a Potter homogenizer with a Teflon pestle rotating at 300 rev./min. A microsomal fraction was prepared and then fractionated on a discontinuous sucrose gradient as described by Toister et al. (1970) . Upper and lower sucrose layers (0.25 M and 57,O, w/v, respectively) were the same as those used by Touster et al. (1970) . The sucrose concentration in the middle layer was varied from 240% to 340% (w/v) in 20% increments to ascertain the best conditions for enrichment of the plasma membrane fraction and separation from endoplasmic reticulum, with the conclusion that for rabbit liver membranes the 3400 concentration used by Touster et al. (1970) was optimal.
The degree of purity of the plasma membrane fractions was estimated by comparing relative specific activities of marker enzymes in homogenates and membrane fractions. 5'-Nucleotidase was used as the plasma membrane marker, succinate: cytochrome c reductase for mitochondria, and NADPH: cytochrome c reductase or glucose-6-phosphatase for endoplasmic reticulum. Glucose-6-phosphatase appeared to be a better marker for endoplasmic reticulum than NADPH: cytochrome c reductase in rabbit liver, because glucose-6-phosphatase activity decreased in inverse proportion to the enrichment of 5'-nucleotidase in plasma membrane fractions. 5'-Nucleotidase activity was estimated in liver homogenates and fractions using the method of Emmelot & Bos (1966) , except that sodium potassium tartrate at 10 mM was included as an inhibitor of acid phosphatases (Michell & Hawthorne, 1965) . Glucose 6-phosphatase was determined in 0.1 mM-Tris/maleate buffer, pH 6.2, containing 4 mM-EDTA and 1 mm NaF (a modification of the original method of Swanson, 1955) . The activity of non-specific phosphatases in both 5'-nucleotidase and glucose-6-phosphatase assays was estimated using 5 mMphenyl disodium orthophosphate as substrate without 5'-AMP or glucose-6-phosphate (Pass et al., 1 981). Inorganic phosphate liberated in the above assays was estimated by the method of King (1932) .
NADPH and succinate: cytochrome c reductases were estimated by the method of de Duve et al. (1955) . The concentration of protein in liver homogenates and fractions was determined by the method of Lowry et al. (1951) , using bovine serum albumin as the standard. RESULTS 
Properties of anti-(GH receptor) MAbs
We previously reported the production and characterization of four MAbs (1, 2, 5 and 7) which react exclusively with GH receptors in rabbit tissue (Barnard et al., 1984 (Fig. 1) Evidence for receptor heterogeneity in microsomal membranes MAb 263 inhibits 500% of oGH binding to rat and rabbit liver microsomes (Fig. 2) . Scatchard (Fig. 3) , as for MAb 7 (Barnard et al., 1984) . Conversely, 125I-MAb 263 binding to rat or rabbit liver microsomes is only 5000 inhibited by excess oGH (Fig. 4) . This shows the presence of MAb 263 epitopes not within 3.5 nm (35 A) of the hormone-binding sites (Tzartos et al., 1981 Fig. 4 (inhibition of MAb 263 binding to rabbit liver microsomes by oGH) where indicated. The points were paired for statistical comparison on the basis of equimolar addition of oGH and MAb 7; *P < 0.025; **P < 0.01. precipitator only (Barnard et al., 1984) , also shows two components with total inhibition (Fig. 5) (Fig. 7) . oGH is capable of inhibiting only 50%O of MAb, 263 binding to these microsomes (Fig. 4) Fig. 14) . and PEG-soluble components (Barnard et al., 1984) . Both components were precipitable by MAbs 1, 2 and 5, enabling detection of additional specific GH binding (Barnard et al., 1984) . Both components of GH binding were also completely immunodepleted by MAb 263. However, MAb 263 does not inhibit hGH binding to the affinity-purified rabbit GH receptor, so that the epitope, although present, is not within 3.5 nm (35 A) of the hormone-binding sites (Tzartos et al., 1981) .
On the other hand, MAb 7 completely inhibits GH binding to the affinity-purified rabbit GH receptor (Barnard et al., 1984) . Thus GH binding sites specifically inhibitable by MAb 263 have apparently not been recovered during the affinity-purification procedure for rabbit GH receptor (see the Discussion). The situation for rat GH receptor is analogous. Although MAb 263 inhibits GH binding to rat liver microsomes and immunoprecipitates affinity-purified rat GH receptor, it does not inhibit hGH binding to the latter.
Antigenic characterization of the liver cytosolic GH binding protein Ymer et al. (1984) recently reported the existence of a PEG-soluble GH binding protein in rabbit liver cytosol which was detectable by gel filtration. We have identified a similar binding protein in our affinity-purified rabbit GH receptor preparations (Barnard et al., 1984) . The three rabbit-specific precipitating MAbs, 1, 2 and 5, were all strongly reactive with the cytosolic component (Fig.  9) . MAb 7 completely inhibits 125I-GH binding to this protein (Fig. 10) . Although immunodepletion studies showed that MAb 263 precipitated this protein, it did not inhibit GH binding, similar to the affinity-purified receptor. Thus, the cytosolic protein shares at least five epitopes with the membrane-associated GH binding proteins.
Scatchard analysis (Fig. 11) shows that there is approx. 7 times more GH binding capacity/g of tissue homogenized in liver cytosol relative to membranes, irrespective of whether homogenization is obtained by Polytron or Dounce homogenization. MAb 7 Endoplasmic reticulum and plasma membrane fractions were added at a dilution which gave 4% specific binding of radioactivity added. Points represent means of triplicate determinations with the S.E.M. values indicated. (0); Endoplasmic reticulum fraction added at 3.8 mg/ml; 0, plasma membrane fraction added at 0.8 mg/ml. The curves do not differ significantly at any of the points (P > 0.1). Parallel dilutions of unrelated ascites fluid (anti-Brucella) were used as binding controls. Non-specific binding was 9% of radioactivity added to plasma membranes and 10%õ f radioactivity added to endoplasmic reticulum fractions.
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The microsomal pellet used in most of our inhibition studies contains vesicles derived from both the blood sinusoidal microvillar region of the hepatocyte plasma membrane and the endoplasmic reticulum (Evans, 1978) . These may differ in their reactivity with our MAbs, giving the appearance of heterogeneity which is not seen by circulating GH. Hence we prepared enriched plasma membranes and endoplasmic reticulum from our microsomal pellets (see the Materials and methods section). Enzyme activities measured in the liver fractions used for inhibition studies are shown in Table 1 . The absolute values and relative specific activities compare favourably with those reported by Touster et al. (1970) and Pass et al. (1981) , in their rat liver fractionation studies. The plasma membrane marker enzyme 5'-nucleotidase has been enriched 20-fold over the levels measured in the crude liver homogenate and close to 6-fold over the microsomal pellet. Plasma membrane contamination of the endoplasmic reticulum was a maximum of 19 o based on the relative specific activitives of 5'-nucleotidase in these fractions. Although endoplasmic reticulum contamination of the plasma membrane fraction appears to be around 50%O, since the specific binding of 125I-GH to endoplasmic reticulum is so much less per mg of membrane protein (10O% /mg for endoplasmic reticulum, 50%O /mg for plasma membrane), it can be readily calculated that any endoplasmic reticulum contribution to shown to be associated with liver microsomes is present in the plasma membrane and does not result from subcellular heterogeneity.
DISCUSSION
The available data in this and our previous study (Barnard et al., 1984) can be accommodated by the model for rabbit GH receptors shown in Fig. 14 Fig. 7 . The model proposes the existence of two kinds of MAb 263 epitope (those associated with the GH binding site and those not so associated). This is compatible with the data depicted in Figs. l(a) and 5. It is possible, however, that the high-affinity MAb 263 epitope corresponds to the epitope found on either type 1 or type 3 receptors. In the latter case, the high-affinity to low-affinity site ratio predicted by the model would be 20: 80; in the former case, 30:70. The data presented in this report do not permit a choice between these two alternatives. The model predicts that inhibition of oGH binding by MAb 7 will be augmented by the combination of MAbs 7 and 263. This is observed (Fig. 6) .
We cannot exclude the possibility of inter-receptor interactions or receptor-membrane interactions contributing in some way to the heterogeneity of receptorMAb interactions. Further studies are being undertaken to investigate the possible role of such interactions.
The proposed model is based on MAb binding characteristics which are reasonably constant in a number of membrane preparations, prepared by diverse means. For six different preparations, the mean level of inhibition by MAb 263 was 48+ 6o% (S.E.M.) These included preparations from frozen liver, from fresh liver, a plasma membrane fraction and two endoplasmic reticulum fractions (the preparation of which involves prolonged ultracentrifugation at 4 C). The average intra-assay variation from the mean level of inhibition in each of these preparations was 400. The relatively small variation between preparations contra-indicates significant proteolytic effects.
We do not believe that the biphasic Scatchard plot (Fig.  1 ) and biphasic inhibition curve (Fig. 5) (Fig. 10) or to affinity-purified GH receptor (Barnard et al., 1984) by Fig. 8 implies that rat GH (which is presumably growth active in the rabbit) does not bind to type 3 receptors, so it seems likely that our type 1 receptor corresponds to the subset of receptors common to rabbit and rat liver which Hughes et al. (1983) have suggested mediate the 'growth' actions of GH. These receptors have high affinity for rat GH and 20 kDa hGH, but are not distinguishable from the second class in terms of oGH binding. We estimate type 1 receptors make up approx.
300% of the total 125I-oGH binding to rabbit liver microsomes.
While the MAbs described here should provide useful tools for defining the functional significance of the three types ofreceptor, it is important to show that the receptor types are present in the plasma membrane, and not simply a product of receptor processing. In this study we have demonstrated that there is no difference between the antigenic characteristics of purified plasma membrane, endoplasmic reticulum or original microsomal membrane preparations with MAb 263 and MAb 7. Hence these three receptor types (including type 2, which is antigenically identical to the cytosolic receptor using the probes described here) are all present in the plasma membrane, and all may mediate biological action(s) of GH. The correspondence between receptor type and biological action as well as the subunit sizes of the receptor types are the subjects of our current investigations. Once these have been established it should be possible to clone each receptor subtype separately and determine the extent of their sequence homologies. This may be of value in determining the role of the abundant cytoplasmic 'receptor', the function of which is presently enigmatic. (NHMRC 322) and a grant by Fielder-Gillespie Ltd. to P. G. B.
